Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpha fetoprotein plasmid DNA vaccine
- Development stage
- Phase 2
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
The alpha fetoprotein plasmid DNA vaccine is a therapeutic cancer vaccine consisting of a plasmid encoding the human or mouse alpha-fetoprotein (AFP) gene. The encoded AFP acts as a tumor-associated antigen (TAA), aiming to induce an immune response—primarily cytotoxic T lymphocyte (CTL) activation—against AFP-expressing tumor cells, such as those found in hepatocellular carcinoma (HCC). The mechanism involves intramuscular administration of the plasmid, leading to in vivo expression of AFP and subsequent presentation by antigen-presenting cells, thereby stimulating anti-tumor immunity. Clinical trials have explored its use alone and in combination with other immunostimulatory agents or viral vector boosts to enhance efficacy[1][2][4]. As of now, it remains investigational and has not received regulatory approval for any indication.
- Other names
- AFP DNA vaccinealpha-fetoprotein DNA vaccine
02
Targets
pMHC (Peptide-MHC complex family)AFP (Alpha-fetoprotein)
Beyond the preview
Go deeper on alpha fetoprotein plasmid DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpha fetoprotein plasmid DNA vaccine.